Viridian Therapeutics’ Chief Financial Officer Seth Harmon filed an amended Form 4 to correct his reported share ownership. The amendment explains that a prior Form 4 filed on March 4, 2025 inadvertently omitted 1,711 shares purchased under the Viridian Therapeutics, Inc. 2016 Employee Stock Purchase Plan.
After reflecting these previously purchased shares, Harmon is shown as directly beneficially owning 1,711 shares of Viridian Therapeutics common stock. The filing does not report any new transactions, but updates the accuracy of his disclosed holdings.
Viridian Therapeutics, Inc. officer Jennifer Tousignant filed an amended Form 4 to correct her reported holdings. The prior filing inadvertently left out 610 shares that were purchased under the Viridian Therapeutics, Inc. 2016 Employee Stock Purchase Plan. After this correction, she is shown as directly owning 610 common shares.
Viridian Therapeutics Chief Operating Officer Thomas W. Beetham reported multiple equity award transactions. On March 2, 2026, he received a stock option grant for 176,550 shares vesting in 48 equal monthly installments, and 35,300 Restricted Stock Units (RSUs) vesting 25% annually over four years.
On March 3, 2026, 9,409 RSUs converted into the same number of common shares, and 3,138 common shares were disposed of at $29.32 per share to cover tax obligations. Following these transactions, he directly held 13,271 common shares and 28,227 RSUs.
Viridian Therapeutics President and CEO Stephen F. Mahoney reported multiple equity award transactions. On March 2, 2026, he was granted stock options for 559,600 shares that vest in 48 equal monthly installments after the grant date, and 111,900 restricted stock units (RSUs) that vest in four annual installments starting March 2, 2026.
On March 3, 2026, 18,357 RSUs converted into an equal number of common shares as part of a prior grant that vests annually from March 3, 2025. To cover tax obligations, 7,627 common shares were disposed of at $29.32 per share through tax withholding, leaving 33,130 common shares held directly.
Viridian Therapeutics Chief Medical Officer Radhika Tripuraneni reported equity awards consisting of stock options and restricted stock units. She acquired stock options for 95,800 shares at an exercise price of $0.00 per share, with the grant dated March 2, 2026. These options vest in 48 equal monthly installments, conditioned on continued service. She also received 19,150 restricted stock units, each representing one share of common stock. The RSUs vest over four years, with 25% vesting on each yearly anniversary of the March 2, 2026 grant date, also subject to continued service.
Viridian Therapeutics, Inc. (VRDN) officer Jennifer D. Tousignant reported a proposed sale of 1,675 common shares, with an aggregate market value of $50,559.88 and an approximate sale date of March 4, 2026. She acquired the shares through restricted stock vesting on March 3, 2026, as compensation. The remarks state that the sale includes an amount necessary to cover a tax obligation resulting from settlement of a vested equity award distribution. In the prior three months, Tousignant reported a sale of 2,272 common shares on December 31, 2025, for gross proceeds of $70,795.52.
Viridian Therapeutics details its shift toward commercialization in serious and rare autoimmune diseases, led by thyroid eye disease (TED) programs. Lead IV antibody veligrotug has completed two global phase 3 trials in active and chronic TED, with a BLA under FDA Priority Review and a PDUFA target date of June 30, 2026. Subcutaneous follow‑on antibody elegrobart is in two phase 3 REVEAL studies, with topline data expected in the first and second quarters of 2026 and an auto‑injector in development for at‑home use. Viridian is also advancing FcRn inhibitors VRDN‑006 and VRDN‑008, plus an early anti‑TSHR antibody for Graves’ disease and TED. Non‑dilutive funding includes a $70 million Japan collaboration with Kissei and a revenue participation deal with DRI Healthcare for up to $300 million tied to U.S. sales milestones.